Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lamivudine 150 mg twice daily Clear all
Completed Phase 3 Interventional Results available

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

NCT00112047
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV), FTC/TDF, FTC/TDF/EFV, Lamivudine/zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
5
States / cities
Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 8, 2026, 5:27 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

NCT00326716
View directory record Official record
Conditions
HIV Infection
Interventions
Atazanavir + Ritonavir + Combivir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
West Palm Beach, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 8, 2026, 5:27 AM EDT
Recruiting Phase 1 Interventional

STARLITE for Unresectable High-Grade Gliomas

NCT06428045
View directory record Official record
Conditions
High Grade Glioma
Interventions
Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy
Procedure · Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 8, 2026, 5:27 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT02016924
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 8, 2026, 5:27 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

NCT01528865
View directory record Official record
Conditions
Lymphoma
Interventions
Lamivudine, Tenofovir disoproxil fumarate
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 8, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

NCT00708162
View directory record Official record
Conditions
HIV Infection
Interventions
Elvitegravir, Raltegravir, EVG placebo, RAL placebo, Background regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
94
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated May 30, 2016 · Synced Oct 8, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

NCT00074581
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Didanosine, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine, Lopinavir/Ritonavir, Nevirapine, Stavudine, Tenofovir disoproxil fumarate, Zidovudine/Lamivudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
3,526 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 8, 2026, 5:27 AM EDT
Terminated Phase 3 Interventional

A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea

NCT00650637
View directory record Official record
Conditions
Diarrhea
Interventions
Calcium Carbonate, nelfinavir, lamivudine, loperamide, Calcium carbonate not administered, lamivudine + zidovudine
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
6
States / cities
Birmingham, Alabama • Fort Lauderdale, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 8, 2026, 5:27 AM EDT
Completed Phase 4 Interventional

An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C

NCT00141284
View directory record Official record
Conditions
HIV Infection, Hepatitis C
Interventions
nelfinavir 1,250 mg twice daily, Zidovudine 300 mg twice daily, Lamivudine 150 mg twice daily
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Bakersfield, California • Miami, Florida • Shreveport, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2011 · Synced Oct 8, 2026, 5:27 AM EDT
Completed Phase 3 Interventional Results available

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

NCT00098293
View directory record Official record
Conditions
HIV-1
Interventions
Maraviroc + Zidovudine/Lamivudine, Efavirenz + Zidovudine/Lamivudine, Maraviroc (UK-427,857) + Zidovudine/Lamivudine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
46
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Oct 8, 2026, 5:27 AM EDT
Completed Phase 1 Interventional Results available

Study of Novel Antiretrovirals in Participants With HIV-1

NCT05585307
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bavtavirine, B/F/TAF, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
38
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 8, 2026, 5:27 AM EDT
Completed Phase 4 Interventional Results available

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

NCT00084136
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Didanosine (enteric-coated), Efavirenz, Emtricitabine, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine/Zidovudine
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
1,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
27
States / cities
Los Angeles, California • Torrance, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 8, 2026, 5:27 AM EDT
Completed Not applicable Interventional

Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV

NCT00006441
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Nelfinavir mesylate, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 8, 2026, 5:27 AM EDT
Completed Phase 4 Interventional Results available

Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

NCT01618305
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/zidovudine, Efavirenz, Raltegravir
Drug
Lead sponsor
Westat
Other
Eligibility
16 Years and older · Female only
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Fort Lauderdale, Florida • New Orleans, Louisiana • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 8, 2026, 5:27 AM EDT